deltatrials
Completed PHASE2 NCT00001680

A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus

Sponsor: National Cancer Institute (NCI)

Conditions Discoid Lupus Erythematosus
Interventions Thalidomide
Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Oct 31, 1997 Completion: Jul 31, 2001

This PHASE2 trial investigates Discoid Lupus Erythematosus and is currently completed. National Cancer Institute (NCI) leads this study, which shows 5 recorded versions since 1997 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Oct 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States